TROPION-Lung01 Study Design and Baseline demographics
Daiichi-Sankyo
Preliminary efficacy data for R-DXd are promising in pretreated OVC patients
70
50
30
•
Median time to response: 6 weeks (95% CI: 5-11)
Median DORª: 11.2 months (95% CI: 3.0-NE)
Median PFSb: 7.9 months (95% CI: 4.4-12.4)
Data cutoff: July 14, 2023.
% Change from baseline in sum
of diameters of target lesions
10
-10
10
-30
550
-50
-70
-90
-110
-130
0
2
4
6
8
4.8 mg/kg (n=9)
10
T
12
14
16
Time (months) from first dose of study drug
Starting dose level
■5.6 mg/kg (n=4)
T
18
T
T
20
20
22
24
26
6.4 mg/kg (n=23)
8.0 mg/kg (n=13)
*Median follow-up for DOR: 5.8 months (range: 1.4-16.8). "Median follow-up for PFS: 5.6 months (range: 0.03-25.1).
The efficacy evaluable population included patients who received 21 dose of study treatment and completed 21 post-baseline tumor assessment or discontinued treatment for any reason. Change from baseline in target tumor size was assessed per RECIST v1.1.
Two patients with no measurable lesions at baseline and one patient who discontinued and did not have a post-baseline tumor assessment were not included in the spider plot.
CI. confidence interval; DOR, duration of response; NE, not estimable, OVC, ovarian cancer, PFS, progression-free survival; RECIST v1.1. Response Evaluation Criteria in Solid Tumors version 1.1.
58
50View entire presentation